1. Scrip
  2. >>Focus On Asia
  3. >>China

After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

But Is Sector Becoming Overcrowded?

 
• By Brian Yang

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.

ChinaPills
BeiGene Set To Get China's Sixth PD-1 Approval • Source: Shutterstock

The recent US approval of BeiGene Ltd.’s BTK inhibitor Brukinsa (zanubrutinib; BGB-3111) for mantle cell lymphoma signaled the arrival of a new era when “Made in China” pharma innovation is able to take on the world, declared an executive for the company.

The clearance, hailed as the first ever for a novel oncology drug in the US for a Chinese drug firm and also BeiGene's first ever approval anywhere, has excited many in the pharma industry at a time when

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia